MEDP

In the past six months, Medpace's stock price has been impacted by several events. On February 9, 2026, the stock price dropped nearly 16% after the company reported its fourth-quarter 2025 financial results, which included a book-to-bill ratio of 1.04, falling short of its guidance of 1.15. On April 23, 2026, the company announced its first-quarter 2026 results, reporting revenue of $706.6 million and diluted earnings per share of $4.28, both exceeding analyst estimates; however, the net book-to-bill ratio declined to 0.88x, attributed to the highest backlog cancellations in over a year, resulting in a significant stock plunge of approximately 23% in late April. On April 24, 2026, Seeking Alpha downgraded Medpace's stock from 'Strong Buy' to 'Buy' due to concerns over rising backlog cancellations and elevated direct costs. On May 2, 2026, Medpace raised its full-year 2026 guidance for revenue and GAAP net income. On May 31, 2026, the planned retirement of President Jesse Geiger was announced. Multiple class-action lawsuits have been filed against Medpace and certain officers, alleging securities fraud for the period of April 22, 2025, to February 9, 2026, claiming the company misled investors by understating cancellation rates and overstating its book-to-bill ratio.